Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc) Read more about Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)
Safety and Efficacy of PC945 in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis Read more about Safety and Efficacy of PC945 in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection Read more about Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
A Peer-Led Intervention to Improve Postpartum Retention in HIV Care Read more about A Peer-Led Intervention to Improve Postpartum Retention in HIV Care
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy Read more about A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer Read more about Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
COVID-19 Vaccine Response in Sickle Cell Disease Read more about COVID-19 Vaccine Response in Sickle Cell Disease
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults Read more about A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
Comparing Inpatient COVID-19 Outcomes in 2 Different PT Dosing Groups Read more about Comparing Inpatient COVID-19 Outcomes in 2 Different PT Dosing Groups